Ultragenyx CEO talks the company’s path to profitability in developing drugs for rare diseases
Dr. Emil Kakkis, Ultragenyx founder & CEO, joins ‘Closing Bell Overtime’ to talk drug trials and development, its path to profitability and more.
Share
Dr. Emil Kakkis, Ultragenyx founder & CEO, joins ‘Closing Bell Overtime’ to talk drug trials and development, its path to profitability and more.
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email CNBC’s Eunice Yoon reports Chinese regulators have suspended market circuit breakers, according to the Shanghai Stock Exchange. 01:45 Thu, Jan 7 20169:43 AM EST
Investors: It’s time to ditch the barbells. So says Larry Glazer, managing partner at Mayflower Advisors, who argued in a Tuesday interview on CNBC’s “Futures Now” that barbell investing — a strategy that involves buying into low-risk, stable assets as well as riskier speculative investments — is putting U.S. investors in an “extreme and dangerous”…
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Hertz CEO Stephen Scherr joins ‘Squawk on the Street’ to discuss news of the company cutting one-third of its electric vehicle fleet over the year, what’s behind the EV selloff, state of the EV rental market, consumer trends, 2024 outlook, and more….
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Vivek Arya, Bank of America managing director, joins ‘TechCheck’ to discuss the most ‘obvious trade’ over the next several years, what will happen to these stocks in the next year and the implications of the recent TSMC investment in the U.S. 04:31…
CNBC’s Andrew Ross Sorkin reports on the latest news.
CNBC’s Jim Cramer explains why he is keeping an eye on shares of Nvidia.